Journal
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES
Volume 1442, Issue 1, Pages 5-16Publisher
WILEY
DOI: 10.1111/nyas.13933
Keywords
ankylosing spondylitis; TNFR1; TNFR2; TNF inhibitors; progranulin
Categories
Funding
- NIH [R01AR062207, R01AR061484, 1R01NS103931]
- DOD [W81XWH-16-1-0482]
Ask authors/readers for more resources
Over the past two decades, considerable advances in our understanding of inflammatory and immune pathways have allowed for the growing use of targeted biologic therapy. Most notably, the introduction of tumor necrosis factor (TNF) inhibitors has dramatically changed the management of autoimmune inflammatory disorders, including ankylosing spondylitis (AS). Despite the efficacy of TNF inhibitors documented in multiple clinical trials, anti-TNF therapy in AS is far from foolproof; it is associated with serious adverse effects and limited response to therapy in some patients. Moreover, specific questions regarding the role of TNF as a mediator of AS remain unanswered. Therefore, additional efforts are needed in order to better understand the role of TNF in the pathogenesis of AS and to develop safer and more effective treatment strategies. The purpose of this review is to better the understanding of the physiologic and pathogenic roles of TNF signaling in the course of AS. Relevant TNF biology and novel approaches to TNF blockade in AS are discussed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available